Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial

Author:

Huang Jing1ORCID,Xiao Juxiang2,Fang Wentao3,Lu Ping4,Fan Qingxia5,Shu Yongqian6ORCID,Feng Jifeng7,Zhang Shu8,Ba Yi9,Zhao Yang10,Liu Ying11,Bai Chunmei12,Bai Yuxian13,Tang Yong14,Song Yan1,He Jie15

Affiliation:

1. Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

2. Department of Medical Oncology The First Affiliated Hospital of Xi'an Jiaotong University Xi'an China

3. Department of Thoracic Surgery Shanghai Chest Hospital, Shanghai Jiao Tong University Shanghai China

4. Department of Oncology First Affiliated Hospital of Xinxiang Medical University Xinxiang China

5. Department of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou China

6. Department of Medical Oncology The First Affiliated Hospital of Nanjing Medical University Nanjing China

7. Department of Medical Oncology Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital Nanjing China

8. Department of Medical Oncology Shandong Cancer Hospital Jinan China

9. Department of Medical Oncology Tianjin Cancer Hospital Tianjin China

10. Department of Biostatistics School of Public Health Nanjing Medical University Nanjing China

11. Department of Medical Oncology Henan Cancer Hospital Zhengzhou China

12. Department of Medical Oncology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

13. Department of Medical Oncology Harbin Medical University Cancer Hospital Harbin China

14. Department of Gastroenterology Affiliated Tumor Hospital, Xinjiang Medical University Urumqi China

15. Department of Thoracic Surgical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3